TLE3 function in rhabdomyosarcoma tumor xenografts.
RNA-seq (gene expression) · human · 20 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Soft tissue sarcomaThis series is part of our curated briefing on it.
- Samples
- 20 samples: 5 × RD non-targeting control vs 5 × RD TLE3KO vs 5 × SJRH30 non-targeting control vs 5 × SJRH30 TLE3KOGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- The Wnt-pathway corepressor TLE3 interacts with the histone methyltransferase KMT1A to inhibit differentiation in RhabdomyosarcomaOncogene · 2024
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE202614_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA836779 and SRA study SRP374515. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 20 samples.
How we read this: 4 replicated groups read from 20 sample titles; they account for 20 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM6125782 RD non-targeting control replicate 1 [100] RD non-targeting control
- GSM6125783 RD non-targeting control replicate 2 [101] RD non-targeting control
- GSM6125784 RD non-targeting control replicate 3 [102] RD non-targeting control
- GSM6125785 RD non-targeting control replicate 4 [103] RD non-targeting control
- GSM6125786 RD non-targeting control replicate 5 [104] RD non-targeting control
- GSM6125787 RD TLE3KO replicate 1 [115] RD TLE3KO
- GSM6125788 RD TLE3KO replicate 2 [116] RD TLE3KO
- GSM6125789 RD TLE3KO replicate 3 [117] RD TLE3KO
- GSM6125790 RD TLE3KO replicate 4 [118] RD TLE3KO
- GSM6125791 RD TLE3KO replicate 5 [119] RD TLE3KO
- GSM6125792 SJRH30 non-targeting control replicate 1 [250] SJRH30 non-targeting co…
- GSM6125793 SJRH30 non-targeting control replicate 2 [251] SJRH30 non-targeting co…
- GSM6125794 SJRH30 non-targeting control replicate 3 [252] SJRH30 non-targeting co…
- GSM6125795 SJRH30 non-targeting control replicate 4 [253] SJRH30 non-targeting co…
- GSM6125796 SJRH30 non-targeting control replicate 5 [254] SJRH30 non-targeting co…
- GSM6125797 SJRH30 TLE3KO replicate 1 [265] SJRH30 TLE3KO
- GSM6125798 SJRH30 TLE3KO replicate 2 [266] SJRH30 TLE3KO
- GSM6125799 SJRH30 TLE3KO replicate 3 [267] SJRH30 TLE3KO
- GSM6125800 SJRH30 TLE3KO replicate 4 [268] SJRH30 TLE3KO
- GSM6125801 SJRH30 TLE3KO replicate 5 [269] SJRH30 TLE3KO
- GSE312030 Combined inhibition of HRAS and MEK induces tumor regression and restores myogenic differentiation in HRAS-mutant rhabdomyosarcoma 159 samples same disease briefing · shares rhabdomyosarcoma
- GSE228127 Multimodal single-cell profiling reveals the enhanced antitumor activity of FGFR4/CD276 BiCisCAR T cells in rhabdomyosarcoma 12 samples same disease briefing · shares rhabdomyosarcoma
- GSE300974 CDK8 Inhibition Releases the Muscle Differentiation Blockade in Fusion-driven Alveolar Rhabdomyosarcoma [RNA-seq] 30 samples same disease briefing · shares rhabdomyosarcoma
- GSE314949 RNA Seq of rhabdomyosarcoma cells with sgRNA targeting oncofusion interacting proteins 30 samples same disease briefing · shares rhabdomyosarcoma
- GSE279954 mRNA/sRNA Co-Sequencing Reveals Multiple New Targeted Therapy Candidates in Rhabdomyosarcoma 26 samples same disease briefing · shares rhabdomyosarcoma
- GSE292872 FANCM is Required for the PAX3::FOXO1-Driven Oncogenic Program in Rhabdomyosarcoma [RNA-Seq] 21 samples same disease briefing · shares rhabdomyosarcoma
- GSE240287 RNA-sequencing of matched samples from rhabdomyosarcoma samples, obtained before therapy and mid-treatment resection 18 samples same disease briefing · shares rhabdomyosarcoma
- GSE286950 PAX3-FOXO1 drives targetable cell state-dependent metabolic vulnerabilities in rhabdomyosarcoma 16 samples same disease briefing · shares rhabdomyosarcoma
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.